Gerrit J. Schuurhuis

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications

Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression.

Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression.

Journal: Leukemia
Published: June 15, 2022

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.

Journal: Cancers
Published: May 07, 2021

Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.

Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.

Journal: Cancers
Published: April 21, 2020

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.

Journal: British journal of haematology
Published: December 17, 2019

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.

Journal: Current protocols in cytometry
Published: November 26, 2019

Can we incorporate MRD assessment into clinical practice in AML?

Can we incorporate MRD assessment into clinical practice in AML?

Journal: Best practice & research. Clinical haematology
Published: March 06, 2019

Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.

Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.

Journal: Leukemia research
Published: January 14, 2019

Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.

Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.

Journal: British journal of haematology
Published: December 07, 2018

Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.

Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.

Journal: Expert review of hematology
Published: November 24, 2018

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Journal: Leukemia research
Published: August 14, 2018

The emerging role of measurable residual disease detection in AML in morphologic remission.

The emerging role of measurable residual disease detection in AML in morphologic remission.

Journal: Seminars in hematology
Published: July 02, 2018

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.

CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia.

Journal: Leukemia
Published: May 17, 2018
Showing 1-12 of 59

Last Updated: 09/26/2026